Form 4: Day One Biopharmaceuticals COO Charles N. York II Reports Stock Transactions
SEC Form 4
Charles N. York II, COO, CFO, and Secretary of Day One Biopharmaceuticals, Inc., reports the acquisition and disposal of common stock and restricted stock units to cover tax liabilities.
Summary
- On May 15, 2025, Charles N. York II, COO, CFO, and Secretary of Day One Biopharmaceuticals, Inc., acquired common stock through the vesting of Restricted Stock Units (RSUs).
- A total of 1,375, 2,250, 6,625 and 6,625 shares were acquired through RSU conversions.
- On May 16, 2025, York disposed of 4,282 shares of common stock at a weighted average price of $6.2579 per share to cover tax liabilities associated with the RSU settlements.
- Following these transactions, York directly owns 265,231 shares of Day One Biopharmaceuticals, Inc.
- York also holds derivative securities in the form of Restricted Stock Units (RSUs) totaling 92,750.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
- Similar filings are made by executives at comparable biopharmaceutical companies like Pfizer, Amgen, and Johnson & Johnson, disclosing their transactions in company stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares, but the overall impact is likely minimal as it is related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of earliest transaction: Acquisition of common stock through RSU vesting. |
| 05/15/2025 | RSU vesting date: 1/16th of the total award vests quarterly on February 15, May 15, August 15 and November 15. |
| 05/16/2025 | Sale of shares to cover tax liability. |
| 05/19/2025 | Date of signature for the Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Day One Biopharmaceuticals, DAWN, Charles N. York II, Restricted Stock Units, RSU, Common Stock, Insider Trading, Tax Liabilities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.